← Torna allo Screener

Arrowhead Pharmaceuticals

ARWR Large Cap

Healthcare · Biotechnology

Aggiornato: May 2, 2026, 22:05 UTC

63,81 €
+1.81% oggi
52W: 10,61 € – 65,48 €
52W Low: 10,61 € Posizione: 97% 52W High: 65,48 €

Metriche Chiave

P/E Ratio
46.76x
Rapporto P/E
Forward P/E
P/E Forward
P/S Ratio
9.6x
Prezzo/Vendite
EV/EBITDA
31.49x
Valore Impresa/EBITDA
Rendimento Dividendi
Rendimento annuale da dividendi
Cap. di Mercato
8,9 Mrd. €
Capitalizzazione di Mercato
Crescita Ricavi
10461.3%
Crescita Ricavi Anno su Anno
Margine di Profitto
18.54%
Margine Netto
ROE
75.5%
Return on Equity
Beta
1.27
Sensibilità al mercato
Interesse Corto
11.98%
% del flottante in vendita allo scoperto
Volume Medio
2,617,159
Volume Medio Giornaliero

Analisi della Valutazione

Segnale
Sopravvalutata
vs. P/E medio S&P 500 (24,7x)
Consenso degli Analisti
Comprare
12 analisti
Prezzo Obiettivo Medio
72,08 €
+12.95% potenziale
Range Obiettivo
29,86 € – 93,83 €

Informazioni sull'Azienda

Settore: Healthcare Industria: Biotechnology Paese: United States Dipendenti: 711 Borsa: NMS

Arrowhead Pharmaceuticals Stock at a Glance

Arrowhead Pharmaceuticals (ARWR) is currently trading at 63,81 € with a market capitalization of 8,9 Mrd. €. The trailing P/E ratio stands at 46.76x. The 52-week range spans from 10,61 € to 65,48 €; the current price is 2.5% below the yearly high. Year-over-year revenue growth stands at +10461.3%. The net profit margin stands at 18.54%.

💰 Dividendo

Arrowhead Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Raccomandazioni degli Analisti

12 analysts rate Arrowhead Pharmaceuticals (ARWR) on consensus: Comprare. The average price target is 72,08 €, implying +12.95% from the current price. Analyst price targets range from 29,86 € to 93,83 €.

Tesi di Investimento: Punti di Forza e Debolezze

Punti di Forza
  • Strong revenue growth of 10461.3% YoY
  • High return on equity (75.5% ROE)
  • High gross margin of 100% — indicates pricing power
  • Analyst consensus: Buy
  • Positive free cash flow
Debolezze
  • Currently flagged as overvalued
  • High short interest (11.98%)
  • Price near 52-week high — limited upside cushion

Panoramica Tecnica

MM 50 Giorni
54,37 €
+17.37% vs. prezzo
MM 200 Giorni
41,44 €
+53.99% vs. prezzo
Sotto Massimo 52S
−2.5%
65,48 €
Sopra Minimo 52S
+501.4%
10,61 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profilo di Rischio

Rischio di Mercato (Beta)
1.27 · Elevated
Moves more than the overall market
Short Interest
11.98% · High
% del flottante in vendita allo scoperto
Debt-to-Equity
124.07 · Elevated
Debito totale / patrimonio

The data points to market-like volatility, elevated short interest (11.98%), higher leverage relative to equity.

Dati di Trading

50-Day MA: 54,37 €
200-Day MA: 41,44 €
Volume: 1,516,042
Volume Medio: 2,617,159
Ratio Corto: 5.82
Rapporto P/B: 18.08x
Debito/Patrimonio: 124.07x
Flusso di Cassa Libero: 146 M €

Where can I buy Arrowhead Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top